Back
Recursion Pharmaceuticals 10K Form
Sell
48
RXRX
Recursion Pharmaceuticals
Last Price:
5.72
Seasonality Move:
6.36%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive RXRX News And Ratings
See the #1 stock for the next 7 days that we like better than RXRX
RXRX Financial Statistics
Sales & Book Value
Annual Sales: | $43.88M |
---|---|
Cash Flow: | $-63.79M |
Price / Cash Flow: | 0 |
Annual Sales: | $1.83 |
Price / Book: | 3.33 |
Profitability
EPS (TTM): | -1.55000 |
---|---|
Net Income (TTM): | $-377.75M |
Gross Margin: | $1.29M |
Return on Equity: | -78.32% |
Return on Assets: | -56.47% |
Recursion Pharmaceuticals Earnings Forecast
Key Recursion Pharmaceuticals Financial Ratios
- The Gross Profit Margin over the past 4 years for RXRX is 2.94%.
- The Selling, General & Administrative Expenses for RXRX have been equal to 252.58% of Gross Profit Margin.
- The Research & Development expenses have been 549.79% of Revenue.
- The Interest Expense is -0.03% of Operating Income.
- The Net Earning history of RXRX is -747.71% of Total Revenues.
- Per Share Earnings over the last 5 years have been positive in 1 years.
Recursion Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | RXRX |
Website: | recursion.com |
Debt
Debt-to-Equity Ratio: | 0.05 |
---|---|
Current Ratio: | 4.35 |
Quick Ratio: | 3.95 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
RXRX Technical Analysis vs Fundamental Analysis
Sell
48
Recursion Pharmaceuticals (RXRX)
is a Sell
Is Recursion Pharmaceuticals a Buy or a Sell?
-
Recursion Pharmaceuticals stock is rated a Sell
The current Recursion Pharmaceuticals [RXRX] share price is $6.04. The Score for RXRX is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.